



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

September 6, 2006

Anil K. Mandal, MD  
Diplomate of the American Board of Internal Medicine  
& Nephrology Fulbright Scholar in Medicine  
240 Southpark Circle East  
St. Augustine, Florida 32086

Dear Dr. Mandal:

Your petition requesting the Food and Drug Administration to restriction or withdrawal of the use of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy in the following conditions, was received by this office on 09/06/2006. It was assigned docket number 2006P-0351/CP1 and it was filed on 09/06/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C. Butler, Director  
Division of Dockets Management  
Office of Management Programs  
Office of Management

2006P.0351

ACK 2



September 6, 2006

Anil K. Mandal, MD  
Diplomate of the American Board of Internal Medicine  
& Nephrology Fulbright Scholar in Medicine  
240 Southpark Circle East  
St. Augustine, Florida 32086

Dear Dr. Mandal:

Your petition requesting the Food and Drug Administration to restriction or withdrawal of the use of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy in the following conditions, was received by this office on 09/06/2006. It was assigned docket number 2006P-0351CP1 and it was filed on 09/06/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in cursive script, reading "Jennie C. Butler", is positioned above the typed name.

Jennie C. Butler, Director  
Division of Dockets Management  
Office of Management Programs  
Office of Management



September 6, 2006

Anil K. Mandal, MD  
Diplomate of the American Board of Internal Medicine  
& Nephrology Fulbright Scholar in Medicine  
240 Southpark Circle East  
St. Augustine, Florida 32086

Dear Dr. Mandal:

Your petition requesting the Food and Drug Administration to restriction or withdrawal of the use of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy in the following conditions, was received by this office on 09/06/2006. It was assigned docket number 2006P-0351CP1 and it was filed on 09/06/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C. Butler, Director  
Division of Dockets Management  
Office of Management Programs  
Office of Management